Oral etoposide in patients with hematological malignancies: A clinical and pharmacokinetic study

Medical Oncology

Volumn 18, Issue 4, 2001, Pages 269-275

  Osby E ^a   Liliemark, E ^a   Bjorkholm M ^a   Liliemark, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hematological malignancies; Oral etoposide; Outcome; Pharmacokinetics; Toxicity

Indexed keywords

ETOPOSIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD DISEASE; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHATIC LEUKEMIA; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; ETOPOSIDE; HEMATOLOGIC NEOPLASMS; HUMANS; MIDDLE AGED; PALLIATIVE CARE; SURVIVAL ANALYSIS;

EID: 0035674736     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:18:4:269     Document Type: Article

References (32)

1. Etoposide and teniposide in the treatment of acute leukemia
2. Etoposide: Twenty years later
3. VP-16-213 monotherapy for remission induction of small cell lung cancer. A randomised trial using three dosage schedules
4. A randomised trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer
5. A randomized trial of two etoposide schedules in small-cell lung cancer: The influence of pharmacokinetics on efficacy and toxicity
6. Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): A randomized trial
7. Phase II study of daily oral etoposide in refractory germ-cell tumors
8. Response of recurrent medulloblastoma to low-dose oral etoposide
9. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy
10. Remission induction in acute myeloid leukemia with oral etoposide
11. Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes
12. Successful treatment of a patient with adult T-cell leukemia by daily oral administration of low-dose etoposide. Decrease in the amount of HTLV-I proviral DNA revealed by the polymerase chain reaction method
13. Oral low-dose etoposide therapy for refractory multiple myeloma with extramedullary involvement
14. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide
15. Chronic daily administration of oral etoposide in refractory lymphoma
16. Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma
17. Chronic daily administration of oral etoposide: A phase I trial
18. Prolonged administration of oral etoposide in non-small-cell lung cancer: A Phase II trial
19. Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia
20. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer
21. Reporting results of cancer treatment
22. Reproducibility of tumour response evaluation in patients with high-grade malignant non-Hodgkin's lymphoma
23. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
24. Natural interferon-α in combination with melphalanprednisone versus melphalanprednisone in the treatment of multiple myeloma stages II and III: A randomized study from the myeloma group of central Sweden
25. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: A pilot study
26. High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukemic cells
27. Ultrafiltration and subsequent high performance liquid chromatography for in vivo determinations of the protein binding of etoposide
28. Oral etoposide is active against platinum-resistant epithelial ovarian cancer
29. Clinical activity of oral etoposide in previously treated metastatic breast cancer
30. Relation of systemic exposure to unbound etoposide and hematological toxicity
31. Predicting etoposide toxicity: Relationship to organ function and protein binding
32. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: A cancer and leukemia group B study (CALGB 9062)